Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Point Of Care Infectious Disease Testing Market By 2029?
The point of care infectious disease testing market has experienced significant expansion in recent years. It is projected to increase from $4.21 billion in 2024 to $4.78 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.6%. Historically, this growth can be attributed to a heightened demand for swift diagnostic methods, a growing prevalence of infectious diseases, increased awareness regarding healthcare, greater healthcare spending, and an uptick in the use of home care and self-testing options.
The point of care infectious disease testing market size is anticipated to undergo swift expansion in the coming years. It is projected to achieve $7.96 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 13.6%. This projected growth throughout the forecast period stems from factors such as increasing demand for rapid diagnostic tools, the rising prevalence of infectious diseases, wider adoption in remote and resource-constrained environments, a move towards decentralized healthcare, and favorable government initiatives and funding. Significant trends expected during this forecast period involve advancements in molecular diagnostics, enhanced point of care testing devices, innovation in biosensors and detection technologies, progress in mobile health applications, and new partnerships between healthcare providers and technology companies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp
Which Major Market Drivers Are Shaping The Future Of The Point Of Care Infectious Disease Testing Market?
The increasing prevalence of contagious diseases is anticipated to fuel the expansion of the point of care infectious disease testing market moving ahead. Contagious diseases are defined as illnesses capable of spreading between individuals via direct contact, airborne particles, or alternative transmission methods. The increasing occurrence of these diseases is primarily attributed to heightened human movement, where increased travel across regions and countries enables quicker and broader dissemination of infectious agents. Point of care infectious disease testing speeds up the identification and diagnosis of contagious illnesses, allowing for prompt medical intervention and lowering the chance of spread within populations. For example, in June 2024, data from the UK Health Security Agency, a UK-based government agency, showed that from week 40 of 2022 to week 15 of 2023, 108 NHS trusts in England documented 1,681 critical care admissions attributed to confirmed influenza. This was a substantial increase compared to the previous flu season, which recorded only 182 admissions across 114 trusts, a number that had risen to 316 by week 39 of 2022. Consequently, the surge in contagious diseases is propelling the expansion of the point of care infectious disease testing market.
How Is The Point Of Care Infectious Disease Testing Market Segmented?
The point of care infectious disease testingmarket covered in this report is segmented –
1) By Product: Kits And Reagents; Instruments
2) By Technology: Lateral Flow Immunoassay; Agglutination Test; Flow-through Test Or Immunoconcentration Assay; Molecular Diagnostics; Other Technologies
3) By Disease: Human Immunodeficiency Virus Point-of-Care Testing; Clostridium Difficile Point-of-Care Testing; Hepatitis B Virus Point-of-Care Testing; Pneumonia or Streptococcus Associated Infections; Respiratory Syncytial Virus Point-of-Care Testing; Human Papillomavirus Point-of-Care Testing; Influenza Or Flu Point-of-Care Testing; Other Diseases
4) By End Use: Hospitals; Diagnostic Centers; Research and Academic Institutes; Homecare Settings; Other End Users
Subsegments:
1) By Kits And Reagents: Test Kits; Reagents
2) By Instruments: Portable Devices; Automated Analyzers
What Trends Are Expected To Drive The Point Of Care Infectious Disease Testing Market?
Major companies in the point-of-care infectious disease testing market are concentrating on integrating innovative technologies, such as proprietary microfluidic technology, to improve test accuracy, reduce the time needed for results, and enhance patient outcomes. Proprietary microfluidic technology refers to specialized systems designed to manipulate small volumes of fluids at the microscale, which enables rapid, precise, and cost-effective analysis. This greatly benefits point of care (POC) infectious disease testing by allowing immediate, on-site pathogen detection, including integrated sample collection, analysis, and result output, thereby accelerating diagnostic speed and accessibility without requiring centralized laboratory testing. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the PA-100 AST System in Europe, introducing the world’s first point-of-care testing solution for directly identifying antimicrobial susceptibility. Utilizing advanced microfluidic technology, this system facilitates quick identification of bacterial infections and evaluation of antimicrobial effectiveness, substantially reducing processing time compared to conventional methods. It includes a compact, desktop-sized analyzer and single-use sample cartridges, making it ideal for near-patient settings like primary care clinics. Designed to enable faster and more accurate antimicrobial therapy decisions, the system contributes to the global fight against antimicrobial resistance by enhancing diagnostic efficiency.
Which Major Industry Participants Are Leading The Point Of Care Infectious Disease Testing Market Growth?
Major companies operating in the point of care infectious disease testing market are Cardinal Health, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, Quest Diagnostics Incorporated, bioMérieux Société Anonyme, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin Società per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Société Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, bioLytical Laboratories Inc.
Download The Full Report For Exclusive Market Findings:
Which Global Regions Are Influencing The Competitive Landscape Of The Point Of Care Infectious Disease Testing Market?
North America was the largest region in the point of care infectious disease testing market in 2024. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Point Of Care Infectious Disease Testing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24382&type=smp
Browse Through More Reports Similar to the Global Point Of Care Infectious Disease Testing Market 2025, By The Business Research Company
Veterinary Point Of Care Diagnostics Global Market Report 2025
Point Of Care Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-global-market-report
Point Of Care Ultrasound Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/point-of-care-ultrasound-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model